Huber Kelly, Patel Poulam, Zhang Lei, Evans Helen, Westwell Andrew D, Fischer Peter M, Chan Stephen, Martin Stewart
School of Molecular Medical Sciences, Division of Clinical Oncology, University of Nottingham, Nottingham University Hospitals, City Hospital Campus, Nottingham NG5 1PB, United Kingdom.
Mol Cancer Ther. 2008 Jan;7(1):143-51. doi: 10.1158/1535-7163.MCT-07-0486.
2-[(1-methylpropyl)dithio]-1H-imidazole (IV-2) is a known inhibitor of the thioredoxin system. It causes the oxidation of cysteine residues from both thioredoxin reductase and thioredoxin, with only the latter leading to irreversible inhibition of protein function. Although IV-2 is considered to be the first specific inhibitor of thioredoxin to undergo evaluation in cancer patients (under the name PX-12), it is unclear whether the oxidative ability of IV-2 is limited to proteins of the thioredoxin family. The current study investigated the specificity of IV-2 by examining its interaction with tubulin, a protein in which cysteine oxidation causes loss of polymerization competence. The cellular effects of IV-2 were examined in MCF-7 breast cancer and endothelial cells (human umbilical vein endothelial cells). Immunocytochemistry revealed a loss of microtubule structure with Western blot analysis confirming that treated cells contained a higher proportion of unpolymerized tubulin. Cell-free tubulin polymerization assays showed a dose-dependent inhibition of tubulin polymerization and depolymerization of preformed microtubules, confirming a direct interaction between IV-2 and tubulin. Further investigation of the tubulin interaction, through analysis of sulfhydryl reactivity and disulfide bond formation, suggested that IV-2 acts through the oxidation of cysteines in tubulin. Biochemical assays indicated that the oxidative properties of IV-2 are not limited to thioredoxin and tubulin, as cysteine-dependent proteases were also inhibited. Breast cancer cells with thioredoxin silenced by short interfering RNA remained sensitive to IV-2, albeit at higher antiproliferative GI50 values than in cells with normal thioredoxin function. These findings show that modulation of targets other than thioredoxin contribute to the effects of IV-2 on proliferating cells.
2-[(1-甲基丙基)二硫代]-1H-咪唑(IV-2)是一种已知的硫氧还蛋白系统抑制剂。它会导致硫氧还蛋白还原酶和硫氧还蛋白中的半胱氨酸残基氧化,只有后者会导致蛋白质功能的不可逆抑制。尽管IV-2被认为是首个在癌症患者中接受评估的硫氧还蛋白特异性抑制剂(商品名PX-12),但尚不清楚IV-2的氧化能力是否仅限于硫氧还蛋白家族的蛋白质。本研究通过检测IV-2与微管蛋白的相互作用来研究其特异性,微管蛋白是一种半胱氨酸氧化会导致聚合能力丧失的蛋白质。在MCF-7乳腺癌细胞和内皮细胞(人脐静脉内皮细胞)中检测了IV-2的细胞效应。免疫细胞化学显示微管结构丧失,蛋白质印迹分析证实处理后的细胞中未聚合微管蛋白的比例更高。无细胞微管蛋白聚合试验显示微管蛋白聚合受到剂量依赖性抑制,且已形成的微管发生解聚,证实了IV-2与微管蛋白之间存在直接相互作用。通过分析巯基反应性和二硫键形成对微管蛋白相互作用进行的进一步研究表明,IV-2通过氧化微管蛋白中的半胱氨酸起作用。生化分析表明,IV-2的氧化特性不仅限于硫氧还蛋白和微管蛋白,因为半胱氨酸依赖性蛋白酶也受到抑制。用短发夹RNA使硫氧还蛋白沉默的乳腺癌细胞对IV-2仍敏感,尽管其抗增殖GI50值高于硫氧还蛋白功能正常的细胞。这些发现表明,除硫氧还蛋白外的其他靶点的调节也有助于IV-2对增殖细胞的作用。